May 21, 2017
SAN DIEGO — Findings presented here indicated that prescription of second-generation antipsychotics with lower metabolic risk have increased from 2006 to 2011, particularly for individuals with several metabolic disorders, but not those with cardiovascular disease.
“We know that patients with severe mental illness have a higher mortality rate than those without, estimates are between 13 and 30 years shorter life expectancy. That mortality gap has been widening in recent years,” Alisa Busch, MD, of McLean Hospital, said during a presentation. “Much of this excess mortality is due to medical comorbidity. We’ve known for a while now that second-generation antipsychotics can increase the risk for metabolic syndrome, which is a combination of different medical conditions —hypertension, hypercholesterolemia, diabetes and obesity — which in turn lead to increased risk for cardiovascular disease.”